Antiviral Activity of Oral Probiotics

John Hale

Status: Unknown

Conditions: Lower Respiratory Tract Infection; Upper Respiratory Tract Infection

Treatments: Dietary Supplement: Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included; Dietary Supplement: Streptococcus salivarius K12 Powder 1 Billion colony forming units /g); Dietary Supplement: Streptococcus salivarius M18 Powder (1 Billion colony forming units /g); Dietary Supplement: Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included

Study type: Interventional

Funder types: Industry

Identifiers

NCT05374070

BLTCT2022/2

Details and patient eligibility

About

The aim of this study is to test saliva samples obtained from healthy human participants for anti-viral activity after they have consumed S. salivarius probiotic in a powder format.

Full description

This is a randomized controlled open pilot study to evaluate saliva samples collected from participants following their consumption of powders containing the commercially marketed probiotic bacterium S. salivarius K12 or S. salivarius M18.

Participants will be randomly assigned to one of the 4 groups consuming probiotic powder containing Streptococcus salivarius K12 or S. salivarius M18 with or without prebiotics (e.g. sugars that may promote probiotic activity). Saliva samples will be collected at predetermined time points pre and post intervention. Antibacterial and Antiviral activity will be determined following established assays. Colonisation efficacy will be determined by enumerating the probiotic in the saliva samples using standard microbiological techniques.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. In general good health 18 - 80 years of age.
2. Practice good oral hygiene.

Exclusion criteria

1. Have a history of autoimmune disease or are immunocompromised.
2. Are on concurrent antibiotic therapy or regular antibiotic use within last 1 week
3. History of allergy (e.g. dairy).

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 4 patient groups

Streptococcus salivarius K12

Active Comparator group

Description:

Streptococcus salivarius K12 (Dose 1: 1 Billion colony forming units /g)

Treatment:

Dietary Supplement: Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)

Streptococcus salivarius K12 with a prebiotic included

Active Comparator group

Description:

Streptococcus salivarius K12 (Dose 1: 1 Billion colony forming units /g)

Treatment:

Dietary Supplement: Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included

Streptococcus salivarius M18

Active Comparator group

Description:

Streptococcus salivarius M18 (Dose 1: 1 Billion colony forming units /g)

Treatment:

Dietary Supplement: Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)

Streptococcus salivarius M18 with a prebiotic included

Active Comparator group

Description:

Streptococcus salivarius M18 (Dose 1: 1 Billion colony forming units /g)

Treatment:

Dietary Supplement: Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included